The relevance of such subtype-specific targets has been exemplified by ESR1 (estrogen receptor α) for luminal-subtype breast cancers; these cancers share not only clinical features such as prognosis and the response to chemotherapy, but also the pattern of gene expression. Here, ESR1 is linked to breast cancer.